Matches in SemOpenAlex for { <https://semopenalex.org/work/W4313385372> ?p ?o ?g. }
Showing items 1 to 65 of
65
with 100 items per page.
- W4313385372 endingPage "212.10" @default.
- W4313385372 startingPage "212.10" @default.
- W4313385372 abstract "Abstract Signaling pathways that activate CREB may inhibit the potency of T cell responses following stimulation. One of the major mechanisms by which this occurs is the sequestration of CBP, which is also an NF-κB binding partner. One of the major molecules that signals through this pathway is vasoactive intestinal peptide (VIP). VIP is a 28 amino acid peptide that is secreted throughout the body by a variety of cell types including immune cells. VIP has shown to be a potent anti-inflammatory molecule with pleiotropic effects on T cells including cell cycle arrest and inhibition of cytokine secretion. The VIP signaling pathway represents a therapeutic target in disease settings in which a more robust T cell response would be beneficial. Acute myeloid leukemia (AML) is a hematological malignancy that has been explored as a candidate for a variety of T cell-based immunotherapies due to weak CD8 responses to AML blasts. We demonstrate here that administration of a hybrid peptide antagonist that blocks VIP signaling enhances CD8 T cell responses in a murine model of AML. CD8 T cells from treated mice showed enhanced secretion of IFN-γ and TNF-α as well as reduced expression of PD-1. These enhanced effector functions lead to a significant survival enhancement, which was lost when treated mice lacked T cells. Additionally, CD8 T cells from antagonist-treated survivors made up the majority of CD3+ cells following transfer to Rag1 knockout recipients. The phenotype of the cells was consistent with enhanced effector functions as transferred CD8+ T cells were predominately CD44+CD62L−. Taken together, these results demonstrate the potential for VIP antagonism as an immunotherapy strategy in settings of hematological malignancies." @default.
- W4313385372 created "2023-01-06" @default.
- W4313385372 creator A5011386306 @default.
- W4313385372 creator A5029229202 @default.
- W4313385372 creator A5043070856 @default.
- W4313385372 date "2016-05-01" @default.
- W4313385372 modified "2023-09-30" @default.
- W4313385372 title "Inhibition of CREB signaling through antagonism of vasoactive intestinal peptide enhances CD8 T cell function in a murine model of AML" @default.
- W4313385372 doi "https://doi.org/10.4049/jimmunol.196.supp.212.10" @default.
- W4313385372 hasPublicationYear "2016" @default.
- W4313385372 type Work @default.
- W4313385372 citedByCount "1" @default.
- W4313385372 countsByYear W43133853722022 @default.
- W4313385372 crossrefType "journal-article" @default.
- W4313385372 hasAuthorship W4313385372A5011386306 @default.
- W4313385372 hasAuthorship W4313385372A5029229202 @default.
- W4313385372 hasAuthorship W4313385372A5043070856 @default.
- W4313385372 hasConcept C118303440 @default.
- W4313385372 hasConcept C154317977 @default.
- W4313385372 hasConcept C167672396 @default.
- W4313385372 hasConcept C170493617 @default.
- W4313385372 hasConcept C202751555 @default.
- W4313385372 hasConcept C203014093 @default.
- W4313385372 hasConcept C2776090121 @default.
- W4313385372 hasConcept C2778690821 @default.
- W4313385372 hasConcept C502942594 @default.
- W4313385372 hasConcept C55493867 @default.
- W4313385372 hasConcept C8330315 @default.
- W4313385372 hasConcept C86803240 @default.
- W4313385372 hasConcept C8891405 @default.
- W4313385372 hasConcept C95444343 @default.
- W4313385372 hasConceptScore W4313385372C118303440 @default.
- W4313385372 hasConceptScore W4313385372C154317977 @default.
- W4313385372 hasConceptScore W4313385372C167672396 @default.
- W4313385372 hasConceptScore W4313385372C170493617 @default.
- W4313385372 hasConceptScore W4313385372C202751555 @default.
- W4313385372 hasConceptScore W4313385372C203014093 @default.
- W4313385372 hasConceptScore W4313385372C2776090121 @default.
- W4313385372 hasConceptScore W4313385372C2778690821 @default.
- W4313385372 hasConceptScore W4313385372C502942594 @default.
- W4313385372 hasConceptScore W4313385372C55493867 @default.
- W4313385372 hasConceptScore W4313385372C8330315 @default.
- W4313385372 hasConceptScore W4313385372C86803240 @default.
- W4313385372 hasConceptScore W4313385372C8891405 @default.
- W4313385372 hasConceptScore W4313385372C95444343 @default.
- W4313385372 hasIssue "1_Supplement" @default.
- W4313385372 hasLocation W43133853721 @default.
- W4313385372 hasOpenAccess W4313385372 @default.
- W4313385372 hasPrimaryLocation W43133853721 @default.
- W4313385372 hasRelatedWork W1568830440 @default.
- W4313385372 hasRelatedWork W181678093 @default.
- W4313385372 hasRelatedWork W1993985418 @default.
- W4313385372 hasRelatedWork W2047209980 @default.
- W4313385372 hasRelatedWork W2054101033 @default.
- W4313385372 hasRelatedWork W2981642747 @default.
- W4313385372 hasRelatedWork W3017248443 @default.
- W4313385372 hasRelatedWork W4320081937 @default.
- W4313385372 hasRelatedWork W2185732136 @default.
- W4313385372 hasRelatedWork W2396811992 @default.
- W4313385372 hasVolume "196" @default.
- W4313385372 isParatext "false" @default.
- W4313385372 isRetracted "false" @default.
- W4313385372 workType "article" @default.